论文部分内容阅读
目的评价FOLFIRI方案治疗晚期胃癌的临床疗效和毒副反应。方法对36例晚期胃癌患者,采用FOLFIRI方案治疗。FOLFIRI方案:伊利替康150mg/m2持续静脉滴入30～90分钟,d1;甲酰四氢叶酸200mg/m2持续静脉滴入2h,d1、2;5-氟尿嘧啶400mg/m2静脉推注,d1、2;600mg/m2静脉微量泵44h持续滴入,14天为1个周期,每连用4个周期评价一次疗效。结果36例患者均可评价疗效和毒副反应,获得CR2例,占5.6%,PR11例,占30.6%,SD13例,占36.1%,PD11例,占30.6%,有效率为36.1%(13/36),中位肿瘤进展时间为4.5个月,中位生存期为9.3个月。毒副反应主要为骨髓抑制、迟发性腹泻。结论对于晚期胃癌患者,FOLFIRI方案是一种有效的、不良反应可以耐受的治疗手段,值得进一步研究。
Objective To evaluate the clinical efficacy and side effects of FOLFIRI regimen in the treatment of advanced gastric cancer. Methods Thirty-six patients with advanced gastric cancer were treated with FOLFIRI regimen. FOLFIRI program: irinotecan 150mg / m2 continuous intravenous infusion of 30 to 90 minutes, d1; leucovorin 200mg / m2 continuous intravenous infusion of 2h, d1,2; 5-fluorouracil 400mg / m2 intravenous injection, d1, 2; 600mg / m2 intravenous micro-pump 44h continuous infusion, 14 days for a cycle, once every 4 cycles to evaluate the efficacy. Results Thirty-six patients were evaluated for efficacy and adverse reactions. CR2 cases accounted for 5.6%, PR 11 cases accounted for 30.6%, SD 13 cases (36.1%), PD 11 cases (30.6%), effective rate 36.1% 36). The median tumor progression was 4.5 months and the median survival was 9.3 months. Toxicity mainly for bone marrow suppression, delayed diarrhea. Conclusion The FOLFIRI regimen is an effective and well tolerated treatment for patients with advanced gastric cancer and deserves further study.